Pharmacological efforts to inhibit hyperactive Shp2 have led to the development of allosteric inhibitors such as SHP099, which selectively stabilizes the inactive conformation of the phosphatase and effectively limit the proliferation of cancer cell lines driven by Ras/Erk pathway mutations (Fedele et al, 2018). Here, PTPN11 is linked to cancer.